Stanford University granted Vermillion exclusive rights to the biomarker panel related to peripheral artery disease (PAD). Stanford and Vermillion have already completed a 540-patient clinical study evaluating the ability of the biomarker panel to classify individuals into high and low risk groups for PAD.
Based on these results, the company plans to further develop the panel for risk assessment. Vermillion will commercialize a blood test utilizing the multimarker panel to stratify an individual’s danger for developing the disease.